Altimmune, Inc. (ALT) Stock Analysis
A live, multi-source view of Altimmune, Inc. (ALT): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Altimmune, Inc.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Sector: Healthcare · Industry: Biotechnology · United States · 57 employees · altimmune.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Altimmune, Inc. (ALT) had a market capitalization of $665.3M (forward -5.1) and a beta of 0.18; the shares traded in a 52-week range of $2.56 – $6.44 (-12.9% over the year).
- Market cap
- $665.3M
- Enterprise value
- $375.0M
- Forward P/E
- -5.1
- PEG ratio
- 32.62
- Price / book
- 1.40
- EPS (trailing)
- $-0.76
- EPS (forward)
- $-0.67
- Payout ratio
- 0.0%
- Ex-dividend date
- 2017-01-20
- 52-week range
- $2.56 – $6.44
- 52-week change
- -12.9%
- Beta
- 0.18
- Average volume
- 4.5M
- Shares outstanding
- 194.5M
- Short % of float
- 26.24%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Altimmune, Inc. (ALT) last closed at $3.29 (the last completed close before that scan).
Technicals at the scan: RSI 57 (neutral territory), price +4.4% versus its 20-day average, 20-day versus 50-day average spread +3.6%, MACD histogram 0.02.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 78/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of ALT; corporate insiders filed 1 buy and 0 sells (1 filer, latest disclosure 2026-08-13). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Jerome Benedict Durso (1B/0S). Who is trading what
RapidTradeView pick record
ALT has been a daily pick 1 time; 1 of 1 graded picks beat SPY over the following five trading days. Most recent: 2026-08-14, rank #3, +7.15% versus SPY (beat). Full scoreboard
What this page covers
RapidTradeView pulls Altimmune, Inc. (ALT) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell ALT.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.